Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

(Reuters) - GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare ...

An FDA advisory committee has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine for use in expectant mothers, potentially opening up a niche for the shot, where it won’t have to face ...

Respiratory syncytial virus prefusion F (RSVpreF ... This study was funded by Pfizer. Several authors declared receiving grants and personal fees from Pfizer paid to the institution outside ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

In the throes of winter's yearly round of respiratory virus outbreaks, it pays to remember what Grandma told you.

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...

Expectant mothers will have access to free vaccines against respiratory syncytial virus (RSV) from next month under a major ...

A virus rapidly spreading in China is also circulating in the United States, causing concern among health experts.

Jan 7 (Reuters) - GSK (GSK.L), opens new tab and Pfizer's (PFE.N), opens new tab respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare ...